PDL BioPharma (PDLI) has risen sharply, recording gains of 12.04% in the past 4 weeks. However, the stock has corrected -2.33% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 12.65% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
The stock has recorded a 20-day Moving Average of 5.02% and the 50-Day Moving Average is 6.65%.The 200 Day SMA reached 4.69%
PDL BioPharma (NASDAQ:PDLI): After opening at $3.23, the stock dipped to an intraday low of $3.21 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $3.37 and the buying power remained strong till the end. The stock closed at $3.35 for the day, a gain of 3.72% for the day session. The total traded volume was 1,721,099. The stocks close on the previous trading day was $3.35.
PDL BioPharma (PDLI) : The consensus price target for PDL BioPharma (PDLI) is $3.75 for the short term with a standard deviation of $0.35. The most optimist securities analyst among the 2 who monitor the stock believes that the stock can reach $4, however, the pessimist price target for the company is $4.
PDL BioPharma, Inc., manages a portfolio of patents and royalty assets, consisting of its Queen et al. patents, license agreements with various biotechnology and pharmaceutical companies, and royalty and other assets acquired. The Company provides non-dilutive growth capital and financing solutions to late-stage public and private healthcare companies and offers immediate financial monetization of royalty streams to companies, academic institutions, and inventors. It is focused on intellectual property asset management, acquiring new income generating assets and maximizing value for its stockholders. The Company receives royalties on a number of marketed products that use its technology and it has liscensed a number of humanized antibody products in late-stage clinical trials. As of December 31, 2014, the Company received royalties on sales of the ten humanized antibody products, which include Avastin, Herceptin, Xolair, Lucentis, Perjeta, Kadcyla, Tysabri, Actemra, Gazyva and Entyvio.